Clinical trials: HF - Heart Failure
Acute Decompensated Heart Failure
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle.
- Trial name
- NCT02617446
- Testing
- Istaroxime
- Where
- 11 sites in China, Italy
- Volunteers
- 120 people
- Sponsor
- Windtree Therapeutics
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Heart Failure
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in…
- Trial name
- FREEDOM-HF (NCT03458325)
- Testing
- Furoscix Infusor
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.
Congestive Heart Failure, Left Ventricular Systolic Dysfunction
Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb.
- Trial name
- SchlaHF (NCT01500759)
- Where
- 199 sites in Australia, Germany
- Volunteers
- 6,876 people
- Sponsor
- ResMed
Congestive Heart Failure
Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar
The objective of this study is to confirm the long-term safety and reliability of the Corox OTW BP left ventricular (LV) pacing lead.
- Trial name
- CELESTIAL (NCT00810264)
- Testing
- CRT Therapy - LV Lead Registry
- Where
- 86 sites in United States
- Volunteers
- 2,499 people
- Sponsor
- Biotronik, Inc.
Heart Failure
Benefits of µCor in Ambulatory Decompensated Heart Failure
Subjects meeting the inclusion/exclusion criteria will wear the µCor for at least 90 days. During the study, clinic follow up will occur every 30 days.
- Trial name
- BMADHF (NCT03476187)
- Testing
- µCor
- Where
- 61 sites in United States, Austria and 1 more
- Volunteers
- 257 people
- Sponsor
- Zoll Medical Corporation
Tachyarrhythmias, Sudden Cardiac Death
SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients
The purpose of this study is to characterize the chronic performance of the St. Jude Medical SJ4 connector and RV high voltage SJ4 leads.
- Conditions
- Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT00940888
- Testing
- SJ4 connector and RV high voltage SJ4 lead
- Where
- United States
- Volunteers
- 1,701 people
- Sponsor
- Abbott Medical Devices
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction
This study will look at how pacing your heart may assist your daily activities and how you are feeling.
- Trial name
- RESET (NCT00670111)
- Testing
- Insignia Plus / Ultra (Guidant/Boston Scientific)
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.
- Trial name
- NCT02548455
- Testing
- Quartet 1457Q LV Lead
- Where
- 30 sites in United States
- Volunteers
- 499 people
- Sponsor
- Abbott Medical Devices
Hypertension
Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
Assess mechanism of action of LCZ696 related to sodium excretion.
- Trial name
- NCT01353508
- Testing
- LCZ696, Valsartan
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Benefits of Microcor in Ambulatory Decompensated Heart Failure
To assess investigator engagement of μCor system data in the context of heart failure management. The μCor system includes a sensor and wearable patch for fluid management.
- Trial name
- BMAD-TX (NCT04096040)
- Testing
- μCor
- Where
- 83 sites in United States, Austria and 2 more
- Volunteers
- 265 people
- Sponsor
- Zoll Medical Corporation
Heart Failure
HF Assessment With BNP in the Home: Part II
HABIT-II is a feasibility study aimed at home monitoring of patients with heart failure. B-type natriuretic peptide (BNP) has strong correlations to the severity of heart failure.
- Trial name
- HABIT-II (NCT02351063)
- Testing
- Changes of heart failure medications
- Where
- 13 sites in United States, Ireland and 4 more
- Volunteers
- 1 people
- Sponsor
- Alere San Diego
Heart Failure
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City…
- Trial name
- CHIEF-HF (NCT04252287)
- Testing
- Canagliflozin 100 mg
- Where
- 18 sites in United States
- Volunteers
- 476 people
- Sponsor
- Janssen Research & Development, LLC
Heart Failure
Attain Stability™ Quad Clinical Study
The purpose of this clinical study is to evaluate the safety and efficacy of the Attain Stability Quadripolar MRI SureScan Left Ventricular (LV) lead (Model 4798).
- Trial name
- NCT03099655
- Testing
- Attain Stability Quad Left Ventricular Pacing Lead
- Where
- 50 sites in United States, Canada and 8 more
- Volunteers
- 471 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Trial name
- NCT00271154
- Testing
- Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
- Where
- 65 sites in United States, Austria and 13 more
- Volunteers
- 684 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals